Septic-Associated Encephalopathy: a Comprehensive Review

Aurélien Mazeraud,Cássia Righy,Eleonore Bouchereau,Sarah Benghanem,Fernando Augusto Bozza,Tarek Sharshar
DOI: https://doi.org/10.1007/s13311-020-00862-1
IF: 6.088
2020-04-01
Neurotherapeutics
Abstract:Septic-associated encephalopathy (SAE) is a key manifestation of sepsis, ranging from delirium to coma and occurring in up to 70% of patients admitted to the ICU. SAE is associated with higher ICU and hospital mortality, and also with poorer long-term outcomes, including cognitive and functional outcomes. The pathophysiology of SAE is complex, and it may involve neurotransmitter dysfunction, inflammatory and ischemic lesions to the brain, microglial activation, and blood–brain barrier dysfunction. Delirium (which is included in the SAE spectrum) is mostly diagnosed with validated scales in the ICU population. There is no established treatment for SAE; benzodiazepines should generally be avoided in this setting. Nonpharmacological prevention and management is key for treating SAE; it includes avoiding oversedation (mainly with benzodiazepines), early mobilization, and sleep promotion.
pharmacology & pharmacy,neurosciences,clinical neurology
What problem does this paper attempt to address?